Asset Details
Do you wish to reserve the book?
Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone
Do you wish to request the book?
Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Development of a chimeric Zika vaccine using a licensed live-attenuated flavivirus vaccine as backbone
2018
Overview
The global spread of Zika virus (ZIKV) and its unexpected association with congenital defects necessitates the rapid development of a safe and effective vaccine. Here we report the development and characterization of a recombinant chimeric ZIKV vaccine candidate (termed ChinZIKV) that expresses the prM-E proteins of ZIKV using the licensed Japanese encephalitis live-attenuated vaccine SA14-14-2 as the genetic backbone. ChinZIKV retains its replication activity and genetic stability in vitro, while exhibiting an attenuation phenotype in multiple animal models. Remarkably, immunization of mice and rhesus macaques with a single dose of ChinZIKV elicits robust and long-lasting immune responses, and confers complete protection against ZIKV challenge. Significantly, female mice immunized with ChinZIKV are protected against placental and fetal damage upon ZIKV challenge during pregnancy. Overall, our study provides an alternative vaccine platform in response to the ZIKV emergency, and the safety, immunogenicity, and protection profiles of ChinZIKV warrant further clinical development.
Given the recent Zika virus (ZIKV) epidemic, development of an effective vaccine is of high importance. Here, the authors use a licensed live-attenuated flavivirus vaccine backbone to develop a ZIKV vaccine and determine immunogenicity, safety and protection profiles in different animal models.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 64/60
/ 82/1
/ 82/80
/ Animals
/ Antibodies, Neutralizing - biosynthesis
/ Antibodies, Viral - biosynthesis
/ Backbone
/ Encephalitis Virus, Japanese - genetics
/ Encephalitis Virus, Japanese - immunology
/ Female
/ Fetuses
/ Humanities and Social Sciences
/ Humans
/ Infectious Disease Transmission, Vertical - prevention & control
/ Male
/ Mice
/ Placenta
/ Proteins
/ Rodents
/ Science
/ Vaccines
/ Vaccines, Attenuated - adverse effects
/ Vaccines, Attenuated - genetics
/ Vaccines, Attenuated - immunology
/ Vaccines, Synthetic - adverse effects
/ Vaccines, Synthetic - genetics
/ Vaccines, Synthetic - immunology
/ Viral Vaccines - adverse effects
/ Viremia - prevention & control
/ Viruses
/ Zika Virus Infection - immunology
